In general, SGLT2 inhibitors have been shown to reduce the risk of atrial arrhythmias such as atrial fibrillation and atrial flutter by 24% but have no effect on ventricular arrhythmias [151], while in patients with DM2, SGLT2 inhibitors reduced atrial arrhythmic events by 19% [152]. The gene discussed is SLC5A2; the disease is Ventricular arrhythmia.